Archvest Wealth Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.68M Sell
1,454
-12
-0.8% -$14.2K 0.84% 24
2026
Q2
$1.76M Buy
1,466
+78
+6% +$79.7K 1.02% 20
2026
Q1
$1.28M Sell
1,388
-873
-39% -$885K 0.82% 20
2025
Q4
$2.43M Buy
2,261
+65
+3% +$62.2K 1.55% 12
2025
Q3
$1.68M Sell
2,196
-39
-2% -$29K 1.48% 15
2025
Q2
$1.74M Buy
2,235
+101
+5% +$78.5K 1.52% 16
2025
Q1
$1.76M Buy
2,134
+28
+1% +$23.3K 1.46% 17
2024
Q4
$1.63M Buy
2,106
+4
+0.2% +$3.31K 1.18% 18
2024
Q3
$1.86M Hold
2,102
– – 1.18% 14
2024
Q2
$1.92M Buy
2,102
+3
+0.1% +$2.4K 1.27% 15
2024
Q1
$1.6M Buy
+2,099
New +$1.49M 1.13% 15

Other funds holding LLY

Archvest Wealth Advisors's LLY Position: Q3 2026 in Review

Archvest Wealth Advisors reduced its Eli Lilly (LLY) stake by 0.82% in Q3 2026, selling an estimated $14.2K and leaving 1,454 shares worth $1.68M. The position accounts for 0.84% of the portfolio, ranked #24.

Archvest Wealth Advisors first reported a position in LLY in Q1 2024 and has held it in 11 quarters since. The position peaked at $2.43M in Q4 2025. 4,606 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • Archvest Wealth Advisors held 1,454 shares of Eli Lilly worth $1.68M as of Q3 2026.
  • Archvest Wealth Advisors sold 12 Eli Lilly shares in Q3 2026, an estimated $14.2K.
  • Eli Lilly made up 0.84% of Archvest Wealth Advisors's portfolio in Q3 2026, its #24 holding.
  • Archvest Wealth Advisors first reported a position in Eli Lilly in Q1 2024 and has held it in 11 quarters since.
  • Archvest Wealth Advisors's Eli Lilly position peaked at $2.43M in Q4 2025.
  • 4,606 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on Archvest Wealth Advisors's 13F filing for Q3 2026, filed 29 Oct 2026.